Faced with these hurdles to gain global market access in the constantly shifting healthcare landscape?
GMAS provides on-demand access to DRG’s expertly curated Global Market Access datasets, country benchmarking tools, commercially focused country-specific analysis on 29 counties, and the first managed entry agreement (MEA) global database.
Continuously updated by country market experts as new data emerges, GMAS allows users to gain a clear understanding of the complex and evolving drivers and barriers to successful global market access by staying abreast of market shifts, key decision-makers, and trends that affect the market access landscape.
GMAS equips biopharma teams with critical insights to:
Four integrated sections provide a detailed deep-dive comparative country analysis, including healthcare systems and processes/details for market authorization, pricing, reimbursement, pharmacoeconomic analysis, and cost-containment strategies.
Geographic Focus – Country summaries and analysis to build country-specific effective market access plans.
Therapeutic Focus – Epidemiology, mortality, and global burden of disease data to identify market opportunities.
Commercial Attractiveness – Proprietary tools for comparative benchmarking to mitigate risk and prioritize assets.
Insights Library – Rich, expertly curated knowledge-sharing documents to explore given markets.
DRG creates enduring working relationships with a focus on collaboration and thought partnership to facilitate our clients’ pursuit of global market access. With a bench of commercially focused analysts and thought leaders—and an industry-leading Client Experience (CE) team—GMAS enables clients to easily: